Cybin (CYBN) versus Its Rivals Head-To-Head Survey

Cybin (NYSE:CYBN) is one of 443 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Cybin to similar businesses based on the strength of its analyst recommendations, dividends, profitability, earnings, valuation, institutional ownership and risk.

Insider & Institutional Ownership

17.9% of Cybin shares are owned by institutional investors. Comparatively, 29.1% of shares of all “Biotechnology” companies are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 25.8% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Cybin has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Cybin’s competitors have a beta of 1.26, meaning that their average stock price is 26% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cybin and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cybin	N/A	-$35.93 million	-44.85
Cybin Competitors	$148.00 million	-$13.34 million	1.78

Cybin’s competitors have higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cybin and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Cybin Competitors	735	2180	5065	56	2.55

Cybin currently has a consensus price target of $50.50, indicating a potential upside of 462.99%. As a group, “Biotechnology” companies have a potential upside of 10.21%. Given Cybin’s stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than its competitors.

Profitability

This table compares Cybin and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-109.05%	-97.85%
Cybin Competitors	-8,581.17%	-107.37%	-23.32%

Summary

Cybin competitors beat Cybin on 9 of the 13 factors compared.

Cybin Company Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.